Discordant effects of β-blockade on central aortic systolic and brachial systolic blood pressure: Considerations beyond the cuff

Pharmacotherapy

Volumn 27, Issue 9 I, 2007, Pages 1322-1333

  Epstein, Benjamin J ^a,b   Anderson, Shawn ^a,b  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

blocker; Blood pressure; Cardiovascular disease; Hypertension

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; ENALAPRIL; EPROSARTAN; FELODIPINE; HYDROCHLOROTHIAZIDE; INDAPAMIDE; LISINOPRIL; LOSARTAN; METOPROLOL; PERINDOPRIL; PLACEBO; RAMIPRIL; VASODILATOR AGENT;

AORTA PRESSURE; BLOOD PRESSURE CUFF; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; BRACHIAL ARTERY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG DOSE ESCALATION; DRUG FATALITY; FOLLOW UP; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART OUTPUT; HEART PROTECTION; HEMODYNAMICS; HUMAN; HYPERTENSION; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PULSE WAVE; RADIAL ARTERY; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT; SPHYGMOMANOMETER; STROKE; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TONOMETRY; VASCULAR RESISTANCE;

ADRENERGIC BETA-ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; AORTA; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; BRACHIAL ARTERY; CARDIOVASCULAR DISEASES; CONTROLLED CLINICAL TRIALS AS TOPIC; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR;

EID: 34548299668     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.27.9.1322     Document Type: Review

References (42)

1. Messerli FH, Beevers DG, Franklin SS, Pickering TG. β-Blockers in hypertension: the emperor has no clothes - an open letter to present and prospective drafters of new guidelines for the treatment of hypertension. Am J Hypertens 2003;16:870-3.
2. Lindholm LH, Carlberg B, Samuelsson O. Should β-blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005;366:1545-53.
3. Messerli FH, Grossman E, Goldbourt U. Are β-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA 1998;279:1903-7.
4. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet 2004;364:1684-9.
5. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
6. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.
7. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.
8. Fournier A, Messerli FH, Achard JM, Fernandez L. Cerebroprotection mediated by angiotensin II: a hypothesis supported by recent randomized clinical trials. J Am Coll Cardiol 2004;43:1343-7.
9. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G, for The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.
10. Sever PS, Poulter NR, Elliot WJ, et al. Blood pressure reduction is not the only determinant of outcome. Circulation 2006;113:2754-72.
11. Beitelshees AL, Zineh I, Yarandi HN, Pauly DF, Johnson JA. Discordant β-blocker effects on clinic, ambulatory resting, and exercise hemodynamics in patients with hypertension. Pharmacotherapy 2006;26:1247-54.
12. Safar ME, Levy BI, Struijker-Boudier H. Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular diseases. Circulation 2003;107:2864-9.
13. Boutouyrie P, Tropeano AI, Asmar R, et al. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertension 2002;39:10-15.
14. Morgan T, Lauri J, Bertram D, Anderson A. Effect of different antihypertensive drug classes on central aortic pressure. Am J Hypertens 2004;17:118-23.
15. Nichols WW. Clinical measurement of arterial stiffness obtained from noninvasive pressure waveforms. Am J Hypertens 2005;18:S3-10.
16. Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the conduit artery function evaluation (CAFE) study. Circulation 2006;113:1213-25.
17. O'Rourke MF, Seward JB. Central arterial pressure and arterial pressure pulse: new views entering the second century after Korotkov. Mayo Clin Proc 2006;81:1057-68.
18. Fogari R, Zoppi A. Antihypertensive drugs and fibrinolytic function. Am J Hypertens 2006;19:1293-9.
19. Brown DW, Giles WH, Croft JB. Left ventricular hypertrophy as a predictor of coronary heart disease mortality and the eflect of hypertension. Am Heart J 2000;140:848-56.
20. de Luca N, Mallion JM, O'Rourke MF, et al. Regression of left ventricular mass in hypertensive patients treated with perindopril/indapamide as a first-line combination: the REASON echocardiography study. Am J Hypertens 2004;17:660-7.
21. Devereux RB, Dahlof B, Gerdts E, et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the losartan intervention for endpoint reduction in hypertension (LIFE) trial. Circulation. 2004;110:1456-62.
22. Devereux RB, Wachtell K, Gerdts E, et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 2004;292:2350-6.
23. Okin PM, Devereux RB, Jem S, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 2004;292:2343-9.
24. Asmar RG, London GM, O'Rourke MF, Safar ME. Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril/indapamide combination in hypertensive patients: a comparison with atenolol. Hypertension 2001;38:922-6.
25. London GM, Asmar RG, O'Rourke MF, et al. Mechanism(s) of selective systolic blood pressure reduction after a low-dose combination of perindopril/indapamide in hypertensive subjects: comparison with atenolol. J Am Coll Cardiol 2004;43:92-9.
26. Chen CH, Ting CT, Lin SJ, et al. Different effects of fosinopril and atenolol on wave reflections in hypertensive patients. Hypertension 1995;25:1034-41.
27. Deary AJ, Schumann AL, Murfet H, Haydock S, Foo RS, Brown MJ. Influence of drugs and gender on the arterial pulse wave and natriuretic peptide secretion in untreated patients with essential hypertension. Clin Sci (Lond) 2002;103:493-9.
28. Hirata K, Vlachopoulos C, Adji A, O'Rourke MF. Benefits from angiotensin-converting enzyme inhibitor 'beyond blood pressure lowering': beyond blood pressure or beyond the brachial artery? J Hypertens 2005;23:551-6.
29. Dhakam Z, McEniery CM, Yasmin, Cockcroft JR, Brown MJ, Wilkinson IB. Atenolol and eprosartan: differential effects on central blood pressure and aortic pulse wave velocity. Am J Hypertens 2006;19:214-19.
30. Neal DA, Brown MJ, Wilkinson IB, Byrne CD, Alexander GJ. Hemodynamic effects of amlodipine, bisoprolol, and lisinopril in hypertensive patients after liver transplantation. Transplantation 2004;77:748-50.
31. O'Rourke MF, Pauca SL. Augmentation of the aortic and central arterial pressure waveform. Blood Press Monit 2004;9:179-85.
32. Nichols WW, Edwards DG. Arterial elastance and wave reflection augmentation of systolic blood pressure deleterious effects and implications for therapy. J Cardiovasc Pharmacol Ther 2001;6:5-21.
33. Nichols WW, Singh BM. Augmentation index as a measure of peripheral vascular disease state. Curr Opin Cardiol 2002;17:543-51.
34. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian cardiac outcomes trial-blood pressure lowering arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005;366:895-906.
35. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the captopril prevention project (CAPPP) randomised trial. Lancet 1999;353:611-16.
36. United Kingdom Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998;317:713-20.
37. Wright JT Jr, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002;288:2421-31.
38. 1 receptor blockade. Am J Cardiovasc Drugs 2004;4:361-8.
39. Epstein BJ, Gums JG. Can the renin-angiotensin system protect against stroke? A focus on angiotensin II receptor blockers. Pharmacotherapy 2005;25:531-9.
40. Pannier BM, Guerin AP, Marchais SJ, London GM. Different aortic reflection wave responses following long-term angiotensin-converting enzyme inhibition and β-blocker in essential hypertension. Clin Exp Pharmacol Physiol 2001;18:1074-7.
41. Taal MW, Brenner BM. Renoprotective benefits of RAAS inhibition: from ACEI to angiotensin II antagonists. Kidney Int 2000;57:1803-17.
42. Casas JP, Chua W, Loukogeorgakis S, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005;366:2026-33.